The cancer genome panel identified mutations in AT-rich interaction domain 1A(<i>ARID1A</i>)and breast cancer susceptibility gene 2 (<i>BRCA2</i>), but there were no available clinical trials or recommended drugs. Here, ARID1A is linked to breast carcinoma.